IDH1 and central nervous system cancer: Ivosidenib (AG-120), for example, has shown promising clinical antitumor activity in glioma patients with IDH1 mutations, and it has been well tolerated by patients, though the optimal dosing for glioma treatment is still under investigation (NCT02073994) [25].